ACTRN12608000463370已完成2 期
Zoledronate for prevention of erosive gout
niversity of Auckland0 个研究点目标入组 100 人开始时间: 2008年9月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •A diagnosis of gout, as described by Wallace.
- •At least one tophus, confirmed by a rheumatologist
- •On stable therapy for gout (no change in the last 3 months)
- •Age over 18 years
- •Able to provide informed consent
排除标准
- •Prolonged treatment with potent bisphosphonates in the last two years
- •Impaired renal function (creatinine clearance <30 ml/minute)
- •Serum calcium < 2.1mmol/L
- •Serum 25(OH)D < 15ng/ml
- •Allergy to bisphosphonate
- •Pregnancy or breastfeeding
- •Unstable systemic medical condition
研究者
相似试验
进行中（未招募）
1 期
Zoledronic acid for prevention of bone loss after bariatric surgeryMorbid obese subjects undergoing bariatric surgeryEUCTR2019-001650-26-DKHospital South West Jutland70
已完成
2 期
ZOledronic acid as DIseAse-modifying drug in Knee osteoarthritis (ZODIAK)10023213osteoarthritisNL-OMON50547niversitair Medisch Centrum Utrecht86
已完成
2 期
Zoledronic acid as Disease-modifying drug in Knee osteoarthritis (ZODIAK)NL-OMON24160niversity Medical Center Utrecht86
进行中（未招募）
4 期
Efficacy of Zoledronate in fracture prevention in osteopenic postmenopausal women.ACTRN12609000593235Professor Ian Reid2,000
已完成
4 期
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric SurgeryBariatric Surgery CandidateNCT03424239Massachusetts General Hospital6